EX-99.1 2 txg-fy2022earningsreleasee.htm EX-99.1 Document

Exhibit 99.1
a10x_logoxhorizontalxfullc.jpg
10x Genomics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Outlook for 2023
Q4 2022 revenue growth of 9% and FY 2022 revenue growth of 5% over the corresponding periods of 2021
PLEASANTON, Calif. February 15, 2023 – 10x Genomics, Inc. (Nasdaq: TXG) today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided outlook for 2023.
Recent Highlights
•Revenue was $156.2 million for the fourth quarter and $516.4 million for the full year of 2022, representing 9% and 5% increases over the corresponding periods of 2021.
•Increased cumulative instruments sold to more than 4,600 as of the end of 2022, driven by continued adoption of Chromium X Series instruments and strong demand for Visium CytAssist.
•Began shipping the Xenium platform for in situ analysis, delivering key performance advantages in data quality, workflow and throughput through highly differentiated chemistry, hardware and software.
•Unveiled new data and showcased key advances and future development directions for all three platforms at the 2023 Advances in Genome Biology and Technology General Meeting.
"The clear highlight of 2022 was the velocity of our innovation engine as our team delivered catalytic launches across all three platforms," said Serge Saxonov, Co-founder and CEO of 10x Genomics. "We finished the year with momentum and in a strong position to capture the massive opportunities ahead."
Fourth Quarter 2022 Financial Results
Revenue was $156.2 million for the three months ended December 31, 2022, a 9% increase from $143.5 million for the three months ended December 31, 2021. This increase was primarily the result of higher consumables revenue in the Americas and EMEA regions partially offset by a decline in China, and overall higher volume of instruments sold including the sales of our newly introduced Xenium instruments, partially offset by unfavorable foreign currency exchange fluctuations.
Gross margin was 76% for the fourth quarter of 2022, as compared to 81% for the corresponding prior year period. The decrease in gross margin was primarily due to change in product mix with newly introduced products.
Operating expenses were $142.5 million for the fourth quarter of 2022, a 8% increase from $131.8 million for the corresponding prior year period. The increase in operating expenses was primarily driven by higher personnel expenses, including stock-based compensation and restructuring costs, increased costs for facilities and information technology to support operational expansion and higher legal expenses, partially offset by lower costs for laboratory materials and supplies and a decrease in marketing expenses.
Operating loss was $23.1 million for the fourth quarter of 2022, as compared to an operating loss of $15.8 million for the corresponding prior year period. Operating loss also includes $41.0 million of stock-based compensation for the fourth quarter of 2022, as compared to $26.9 million for the fourth quarter of 2021.
Net loss was $17.2 million for the fourth quarter of 2022, as compared to a net loss of $18.4 million for the corresponding prior year period.
Full Year 2022 Financial Results
Revenue was $516.4 million for the year ended December 31, 2022, a 5% increase from $490.5 million for 2021.

Gross margin was 77% for full year 2022, as compared to 85% for 2021. The decrease in gross margin was primarily due to higher accrued royalties including a one-time reversal of $14.7 million of previously accrued royalties in 2021, change in product mix with newly introduced products and increased manufacturing and logistics costs.
1
a10x_logoxhorizontalxfullc.jpg

Operating expenses were $564.0 million for full year 2022, as compared to $468.7 million for 2021, an increase of 20%. The increase in operating expenses was primarily due to higher personnel expenses, including stock-based compensation and restructuring costs, increased expenses related to laboratory materials and supplies to support our research and development efforts and increased facilities and information technology costs to support operational expansion, partially offset by lower legal expenses, consulting and professional services and marketing expenses.

Operating loss was $167.9 million for full year 2022, as compared to an operating loss of $52.3 million for 2021. This includes $136.8 million of stock-based compensation for full year 2022, as compared to $96.0 million for full year 2021.

Net loss was $166.0 million for full year 2022, as compared to a net loss of $58.2 million for 2021.

Cash and cash equivalents and marketable securities were $430.0 million as of December 31, 2022.
2023 Financial Guidance
10x Genomics expects full year 2023 revenue to be in the range of $580 million to $600 million, representing 12% to 16% growth over full year 2022 revenue.
Webcast and Conference Call Information
10x Genomics will host a conference call to discuss the fourth quarter and full year 2022 financial results, business developments and outlook after market close on Wednesday, February 15, 2023 at 1:30 PM Pacific Time / 4:30 PM Eastern Time. A webcast of the conference call can be accessed at http://investors.10xGenomics.com. The webcast will be archived and available for replay for at least 45 days after the event.
About 10x Genomics
10x Genomics is a life science technology company building products to interrogate, understand and master biology to advance human health. Our integrated solutions include instruments, consumables and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. 10x Genomics products have been adopted by researchers around the world including in all of the top 100 global research institutions as ranked by Nature in 2021 based on publications and all of the top 20 global pharmaceutical companies by 2021 research and development spend and have been cited in over 4,500 research papers on discoveries ranging from oncology to immunology and neuroscience. Our patent portfolio comprises more than 1,750 issued patents and patent applications.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. All statements, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “may,” “might," "will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential,” "would," "likely," "seek" or “continue” or the negatives of these terms or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include statements regarding 10x Genomics, Inc.’s expectations regarding our business operations, anticipated size of market opportunities and our ability to capture them, expected performance advantages and benefits of using our products and services and financial performance and results of operations, including our expectations regarding revenue and guidance. These statements are based on management’s current expectations, forecasts, beliefs, assumptions and information currently available to management, and actual outcomes and results could differ materially from these statements due to a number of factors. The material risks and uncertainties that could affect 10x Genomics, Inc.’s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the documents 10x Genomics, Inc. files with the Securities and Exchange Commission from time to time.
Although 10x Genomics, Inc. believes that the expectations reflected in the forward-looking statements are reasonable, it cannot provide any assurance that these expectations will prove to be correct nor can it guarantee that the future results, levels of
2
a10x_logoxhorizontalxfullc.jpg
activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or occur. These forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments 10x Genomics may make. Further, such forward-looking statements may not accurately or fully reflect the potential impact that the COVID-19 pandemic may have on the business, financial condition, results of operations and cash flows of 10x Genomics, Inc. The forward-looking statements in this press release are based on information available to 10x Genomics, Inc. as of the date hereof, and 10x Genomics, Inc. disclaims any obligation to update any forward-looking statements provided to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing 10x Genomics, Inc.’s views as of any date subsequent to the date of this press release.
Disclosure Information
10x Genomics uses filings with the Securities and Exchange Commission, our website (www.10xgenomics.com), press releases, public conference calls, public webcasts and our social media accounts as means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD.
Contacts
Investors: investors@10xgenomics.com
Media: media@10xgenomics.com
3
a10x_logoxhorizontalxfullc.jpg
10x Genomics, Inc.
Consolidated Statement of Operations
(Unaudited)
(In thousands, except share and per share data)
Three Months Ended
December 31,		Year Ended
December 31,
2022202120222021
Revenue$156,232 $143,530 $516,409 $490,490 
Cost of revenue (1)36,827 27,597 120,386 74,091 
Gross profit119,405 115,933 396,023 416,399 
Operating expenses:
Research and development (1)63,614 61,884 265,667 211,752 
Selling, general and administrative (1)78,887 69,879 298,300 257,560 
Accrued contingent liabilities— — — (660)
Total operating expenses142,501 131,763 563,967 468,652 
Loss from operations(23,096)(15,830)(167,944)(52,253)
Other income (expense):
Interest income2,815 49 6,647 206 
Interest expense(125)(217)(476)(866)
Other income (expense), net3,995 5 (198)(802)
Total other income (expense) 6,685 (163)5,973 (1,462)
Loss before provision for income taxes(16,411)(15,993)(161,971)(53,715)
Provision for income taxes804 2,456 4,029 4,508 
Net loss$(17,215)$(18,449)$(166,000)$(58,223)
Net loss per share, basic and diluted$(0.15)$(0.16)$(1.46)$(0.53)
Weighted-average shares used to compute net loss per share, basic and diluted114,757,572 111,896,429 113,858,684 110,347,937 
(1)Includes stock-based compensation expense as follows:
Three Months Ended
December 31,		Year Ended
December 31,
(in thousands)2022202120222021
Cost of revenue$1,511 $1,048 $5,259 $3,231 
Research and development17,865 11,808 59,211 41,970 
Selling, general and administrative21,598 14,048 72,378 50,761 
Total stock-based compensation expense$40,974 $26,904 $136,848 $95,962 









4
a10x_logoxhorizontalxfullc.jpg
10x Genomics, Inc.
Consolidated Balance Sheets
(Unaudited)
(In thousands, except share and per share data)
December 31,
20222021
Assets
Current assets:
Cash and cash equivalents$219,746 $587,447 
Marketable securities210,238 — 
Restricted cash2,633 1,028 
Accounts receivable, net104,211 85,254 
Inventory81,629 59,966 
Prepaid expenses and other current assets16,578 13,896 
Total current assets635,035 747,591 
Property and equipment, net289,328 169,492 
Restricted cash4,974 7,598 
Operating lease right-of-use assets69,882 60,918 
Goodwill4,511 4,511 
Intangible assets, net22,858 25,397 
Other noncurrent assets2,392 3,319 
Total assets$1,028,980 $1,018,826 
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable$21,599 $17,351 
Accrued compensation and related benefits32,675 31,626 
Accrued expenses and other current liabilities59,779 50,909 
Deferred revenue7,867 5,340 
Operating lease liabilities9,037 5,131 
Total current liabilities130,957 110,357 
Accrued license fee, noncurrent— 5,814 
Operating lease liabilities, noncurrent86,139 76,847 
Other noncurrent liabilities6,141 8,240 
Total liabilities223,237 201,258 
Commitments and contingencies
Stockholders' equity:
Preferred stock, $0.00001 par value; 100,000,000 shares authorized, no shares issued or outstanding as of December 31, 2022 and December 31, 2021
— — 
Common stock, $0.00001 par value; 1,100,000,000 shares authorized and 115,195,009 and 112,514,977 shares issued and outstanding as of December 31, 2022 and 2021
2 2 
Additional paid-in capital1,839,397 1,680,865 
Accumulated deficit(1,029,321)(863,321)
Accumulated other comprehensive income (loss)(4,335)22 
Total stockholders’ equity805,743 817,568 
Total liabilities and stockholders’ equity$1,028,980 $1,018,826 
5